Contents

27 May 2020
Vol 12, Issue 545

About The Cover

Cover image expansion

ONLINE COVER Buttressing the Barrier. Cells bound by a fluorescently labeled protease inhibitor are shown in green in this image of a mouse esophagus. A new study from Azouz et al. indicates that protease inhibition may be useful for treating eosinophilic esophagitis (EoE), a disease with limited therapeutic options. EoE is driven by an immune reaction to food that damages the esophagus, and involves inflammation and epithelial barrier disruption. This study demonstrated unrestrained protease activity in esophageal samples from individuals with EoE and in an EoE mouse model and dissected relevant molecules in the pathophysiology of this disease. Two different protease inhibitors that alleviated symptoms in the mouse model have potential for rapid translation. [CREDIT: CHRIS WOODS, NURIT AZOUZ, MARC ROTHENBERG]